Close Menu

NEW YORK – Fluidigm reported after the close of the market on Thursday that its third quarter revenues jumped 50 percent year over year driven largely by products related to COVID-19 testing and research.

For the three months ended Sept. 30, 2020, Fluidigm tallied $39.9 million in revenues compared to $26.5 million a year ago and well above analysts' consensus estimate of $32.5 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Feb
23
Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 

Feb
24
Sponsored by
SCHOTT MINIFAB

Developing a fully integrated consumable cartridge for an automated diagnostic platform is a significant challenge. More challenging still is developing such a cartridge in response to a deadly global virus pandemic amid market uncertainty and extraordinary time constraints.